Sökning: onr:"swepub:oai:DiVA.org:uu-498975" > Haematological mali...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05145naa a2200517 4500 | |
001 | oai:DiVA.org:uu-498975 | |
003 | SwePub | |
008 | 230323s2022 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:151829042 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4989752 URI |
024 | 7 | a https://doi.org/10.1136/rmdopen-2022-0027762 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1518290422 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cordtz, Rene Lindholmu Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark4 aut |
245 | 1 0 | a Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors :b a Nordic cohort study |
264 | c 2022-12-23 | |
264 | 1 | b BMJ Publishing Group Ltd,c 2022 |
338 | a electronic2 rdacarrier | |
520 | a Objectives To evaluate the risk of haematological malignancies in patients with psoriatic arthritis (PsA) overall, and in relation to treatment with tumour necrosis factor inhibitors (TNFi).Methods We identified that patients with PsA starting a first TNFi from the clinical rheumatology registers (CRR) in the five Nordic countries (n=10 621) and biologics-naive PsA patients from (1) the CRR (n=18 705) and (2) the national patient registers (NPR, n=27 286, Sweden and Denmark) from 2006 through 2019. For Sweden and Denmark, general population comparators were matched 5:1 to PsA patients on birth year, year at start of follow-up and sex. By linkage to the national cancer registers in all countries, we collected information on haematological malignancies overall, and categorised into lymphoid or myeloid types. We estimated incidence rate ratios (IRRs) with 95% CIs using modified Poisson regression for TNFi-treated versus biologics-naive PsA patients and versus the general population adjusted for age, sex, calendar period and country.Results During 59 827 person-years, 40 haematological malignancies occurred among TNFi-treated patients with PsA resulting in a pooled IRR of 0.96 (0.68-1.35) versus biologics-naive PsA from CRR and an IRR of 0.84 (0.64-1.10) versus biologics-naive PsA from NPR. The IRR of haematological malignancies in PsA overall versus general population comparators was 1.35 (1.17-1.55). The estimates were largely similar for lymphoid and myeloid malignancies.Conclusions Treatment with TNFi in patients with PsA was not associated with an increased incidence of haematological malignancies. Conversely, a moderately increased underlying risk was seen in patients with PsA compared with the general population. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
700 | 1 | a Askling, Johanu Karolinska Institutet4 aut |
700 | 1 | a Delcoigne, Benedicteu Karolinska Institutet4 aut |
700 | 1 | a Smedby, Karin E.u Karolinska Institutet4 aut |
700 | 1 | a Baecklund, Eva,d 1956-u Uppsala universitet,Reumatologi4 aut0 (Swepub:uu)evaba786 |
700 | 1 | a Ballegaard, Christineu Univ Copenhagen, Bispebjerg & Frederiksberg Hosp, Parker Inst, Copenhagen, Denmark4 aut |
700 | 1 | a Isomaki, Piau Tampere Univ Hosp, Ctr Rheumatol, Tampere, Finland.;Fac Med & Hlth Technol, Tampere, Finland4 aut |
700 | 1 | a Aaltonen, Kalleu Minist Social Affairs & Hlth, Pharmaceut Pricing Board, ROB FIN, Helsinki, Finland4 aut |
700 | 1 | a Gudbjornsson, Bjornu Univ Iceland, Landspitali Univ Hosp Iceland, Ctr Rheumatol Res, Reykjavik, Iceland.;Univ Iceland, Fac Med, Reykjavik, Iceland4 aut |
700 | 1 | a Love, Thorvardur Jonu Univ Iceland, Fac Med, Reykjavik, Iceland.;Landspitali Univ Hosp Iceland, Dept Sci, Reykjavik, Iceland4 aut |
700 | 1 | a Provan, Sella Aarrestadu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway4 aut |
700 | 1 | a Michelsen, Brigitteu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway.;Sorlandet Hosp Kristiansand, Div Rheumatol, Kristiansand, Norway4 aut |
700 | 1 | a Sexton, Josephu Diakonhjemmet Hosp, Ctr Treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway4 aut |
700 | 1 | a Dreyer, Leneu Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark.;Aalborg Univ, Dept Clin Med, Aalborg, Denmark4 aut |
700 | 1 | a Hellgren, Karinu Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Aalborg Univ Hosp, Ctr Rheumat Res Aalborg, Aalborg, Denmark4 org |
773 | 0 | t RMD Opend : BMJ Publishing Group Ltdg 8:2q 8:2x 2056-5933 |
856 | 4 | u https://doi.org/10.1136/rmdopen-2022-002776y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1745681/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-498975 |
856 | 4 8 | u https://doi.org/10.1136/rmdopen-2022-002776 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:151829042 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.